Interrupters of VAscular daMAge in Malignant Hypertension

CompletedOBSERVATIONAL
Enrollment

45

Participants

Timeline

Start Date

February 7, 2022

Primary Completion Date

October 11, 2024

Study Completion Date

October 11, 2024

Conditions
Malignant Hypertension
Interventions
BIOLOGICAL

analyse of angiogenic, vasoactive and VEGF systems

the angiogenic, vasoactive and VEGF systems will be analysed through blood and urine sampling. These samples will be collected at the time of malignant hypertension diagnosis and repeated one month later, in 30 patients (patients group). The same tests will be performed once in 15 patients with severe non-malignant hypertension, constituting the control group.

Trial Locations (7)

Unknown

Hôpital Avicenne, Bobigny

CHU de Bordeaux, Bordeaux

Hôpital Bichat, Paris

Hôpital Européen Georges Pompidou, Paris

Hôpital Tenon, Paris

Chu Rangueil, Toulouse

CHU de Tours, Tours

All Listed Sponsors
lead

Centre Hospitalier de PAU

OTHER